Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSIST-5: 5-Year Adjuvant Imatinib in GIST
NCT00867113Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Started Jul 2009; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00867113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00867113.